SNDX241220C20000
- 0.15
- -0.10-40.00%
Syndax Pharmaceuticals Newsroom
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $38
Syndax Pharmaceuticals Is Maintained at Buy by Citigroup
Syndax Pharmaceuticals Analyst Ratings
Scotiabank Maintains Syndax Pharmaceuticals(SNDX.US) With Hold Rating, Maintains Target Price $18
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $33 to $51
Syndax Pharmaceuticals (SNDX) Gets a Buy From Barclays
Syndax Pharmaceuticals' Promising Outlook: Revumenib Approval and Market Potential Justify Buy Rating
Syndax Pharmaceuticals (SNDX) Gets a Buy From TD Cowen
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $51
Syndax Pharmaceuticals Analyst Ratings
Early FDA Approval of Revuforj Boosts Syndax Pharmaceuticals' Prospects and Supports Overweight Rating
Mizuho Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $31
Scotiabank Maintains Syndax Pharmaceuticals(SNDX.US) With Hold Rating, Cuts Target Price to $18
BTIG Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $35
Syndax Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Syndax Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $49
Promising Market Potential and Efficacy of Syndax Pharmaceuticals' Revumenib Justify Buy Rating
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $33